Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)
This NIH (R01) opportunity funds research developing novel screening approaches or therapies for fatal or disabling conditions identified through newborn screening, including high-priority genetic …
- Deadline
- Nov 16, 2027
- Posted
- Dec 2, 2024
- Award amount
- Amount not specified
- Focus areas
- HealthIncome Security and Social Services
Don’t miss this deadline
We’ll email you before Nov 16, 2027 so you have time to apply.
In plain English
This NIH (R01) opportunity funds research developing novel screening approaches or therapies for fatal or disabling conditions identified through newborn screening, including high-priority genetic conditions. It is intended for research and academic institutions rather than individuals or general nonprofits/small businesses. No specific award amount is stated.
AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.
Who can apply
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
About this grant
This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future.Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.
Let AI draft your application
Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.
Application Kit — $49 one-time
Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.
Get the Application Kit →Related grants
Other open grants funding Health and Income Security and Social Services — soonest deadline first.
BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due Sep 28, 2026
BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due Sep 28, 2026
Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)
National Institutes of Health · Amount varies · Due in 17 days
National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional)
National Institutes of Health · Amount varies · Due in 17 days
Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)
National Institutes of Health · Amount varies · Due in 17 days
Social disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due in 17 days
Also listed under National Institutes of Health, Health Grants and Social Services Grants.
Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.